Association of Neurohormonal Antagonists on Incident Cardiotoxicity in Patients With Breast Cancer
Section snippets
Methods
This study was approved by the institutional review board. This was a single-center, retrospective cohort study of patients diagnosed with breast cancer from January 2014 to December 2021. Patients were included in the study if they had received a diagnosis of breast cancer, received treatment for their cancer with anthracycline and/or trastuzumab, and had an echocardiogram performed before and after treatment initiation. Patients were excluded from the study if they did not receive treatment
Results
Over the study period, 937 patients were screened and 459 met the inclusion criteria. Baseline characteristics are shown in Table 1. The average age of all participants was 55 years (SD ± 12). A total of 375 were White (82%), 51 were Black (11%), and 33 were self-reported as “Other” (7%) for their racial background. All patients were women and 113 had triple negative breast cancer (25%). A total of 239 were treated with only trastuzumab (52%), 158 with only anthracycline (34%) and 62 were
Discussion
The principal finding of our study showed no association between previous neurohormonal antagonist use and development of cardiotoxicity. This finding remained consistent even after matching for relevant baseline characteristics. The time-to-event analysis failed to show significant differences between treatment and nontreatment groups; a finding that also persisted after matching. Secondarily, increased age was a notable risk factor and emphasizes the importance of screening for asymptomatic
Disclosures
The authors have no conflicts of interest to declare.
References (30)
- et al.
Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Lancet
(2017) - et al.
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)
J Am Coll Cardiol
(2013) - et al.
Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial
J Am Coll Cardiol
(2018) - et al.
Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial
Eur J Cancer
(2018) - et al.
Randomized trial of Lisinopril versus Carvedilol to prevent Trastuzumab cardiotoxicity in patients with breast cancer
J Am Coll Cardiol
(2019) - et al.
Evaluation and management of patients with heart disease and cancer: cardio-oncology
Mayo Clin Proc
(2014) - et al.
Cardio-oncology in the older adult
J Geriatr Oncol
(2017) - et al.
The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review
JACC CardioOncol
(2022) - et al.
Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study
Breast Cancer Res
(2011) Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Heart
(2018)
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
Cancer
Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer
Curr Breast Cancer Rep
Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer
JAMA Oncol
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
J Clin Oncol
Long-term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial
J Clin Oncol
Cited by (0)
Funding: None.